Suppression of bleomycin-induced increased production of nitric oxide and NF-kB activation by treatment with taurine and niacin.
Giri
S N
SN
Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, 95616, USA.
Gurujeyalakshmi
G
G
Wang
Y
Y
D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D001761:Bleomycin / Q000494:pharmacology*; D004268:DNA-Binding Proteins / Q000378:metabolism; D006909:Hydroxyproline / Q000378:metabolism; D020672:I-kappa B Proteins; D007375:Interleukin-1 / Q000378:metabolism; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D009525:Niacin / Q000008:administration & dosage / Q000494:pharmacology*; D009569:Nitric Oxide / Q000096:biosynthesis*; D019001:Nitric Oxide Synthase / Q000235:genetics / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D016877:Oxidants / Q000494:pharmacology*; D013654:Taurine / Q000008:administration & dosage / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000975:Antioxidants; D004268:DNA-Binding Proteins; D020672:I-kappa B Proteins; D007375:Interleukin-1; D016328:NF-kappa B; C000606205:Nfkbia protein, mouse; D016877:Oxidants; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D001761:Bleomycin; D000072000:NF-KappaB Inhibitor alpha; D013654:Taurine; D009525:Niacin; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; D006909:Hydroxyproline